Inclusion Criteria:

1. Histologically and/or cytologically confirmed malignant solid tumor that is
refractory to standard therapies, or for which no standard therapies exist.

2. Patients must have at least one measurable site of disease according to RECIST (see
Appendix 1) criteria that has not been previously irradiated. If the patient has had
previous radiation to the marker lesion(s), there must be evidence of progression
since the radiation

3. Age ≥ 18 years

4. Karnofsky Performance status ≥ 80% (see Appendix 2)

5. Adequate bone marrow function as shown by:

1. ANC ≥ 1.5 x 109/L

2. Platelets ≥ 100 x 109/L

3. Hemoglobin >9 g/dL; Erythropoietin and transfusion support is permitted provided
treatments are not required more than every 8 weeks.

6. Adequate liver function as shown by:

1. serum bilirubin ≤ 1.5 x ULN

2. INR ≤ 1.5

3. ALT and AST ≤ 2.5x ULN (≤ 5x ULN in patients with liver metastases)

7. Adequate renal function: creatinine clearance (estimated) ≥ 40 cc/min

8. Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤
2.5 x ULN. NOTE: Use of standard lipid lowering agents (see Section 10.3.6 for
guidance) is permitted to meet eligibility.

9. Fasting blood sugar <160 mg/dL.

10. Baseline MUGA or ECHO must demonstrate LVEF ≥ 50%

11. TSH and free T4 within normal limits; Patients are permitted to receive thyroid
hormone supplements to treat underlying hypothyroidism.

12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
within 7 days from day 1 of study drug and must be willing to use two methods of
contraception, one of them being a barrier method during the study and for 3 months
after last study drug administration

13. Signed informed consent

Exclusion Criteria:

1. Patients currently receiving anticancer therapies or who have received anticancer
therapies within 4 weeks from day 1 of study drug (including chemotherapy, radiation
therapy, antibody based therapy, etc.)

2. Patients who:

1. have had a major surgery or significant traumatic injury within 4 weeks from day
1 of study drug,

2. have not recovered from the side effects of any major surgery (defined as
requiring general anesthesia) or

3. are anticipated to require major surgery during the course of the study.

3. Patients with a known hypersensitivity to experimental drugs (or classes of drugs) or
their excipients

4. Patients receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent with the following exceptions:

- Intermittent steroids ( not to exceed 4 mg every day) may be used on an
as-needed basis (e.g. treatment for chemotherapy-related nausea.)

- Patients on physiologic replacement doses of steroids due to adrenal
insufficiency for any reason may remain on these medications.

- Topical, inhaled or intra-articular corticosteroids

5. Patients should not receive immunization with attenuated live vaccines within one
week of day 1 of study drug or during study period

6. Active brain or leptomeningeal metastases, including patients who continue to require
glucocorticoids for brain or leptomeningeal metastases. Treated, asymptomatic
metastases are permitted provided the patient has been off steroids for at least 1
month prior to day 1 of study drug.

7. Clinically significant arrhythmias including complete left bundle branch block or use
of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of
ventricular tachyarrhythmias, 2nd degree AV block type II, 3rd degree AV block
clinically significant resting bradycardia (<50 beats per minute), QTcF > 450 msec on
screening ECG.

8. Presence of poorly controlled atrial fibrillation (ventricular heart rate >100 bpm)

9. Previous history of CVA, TIA, angina pectoris, acute MI or history of recent
re-perfusion procedures (e.g. PTCA) within 6 months from day 1 of study drug.

10. Congestive heart failure (New York Heart Association (NYHA classification, see
Appendix 4 functional classification III-IV).

11. Fasting blood sugar > 160 mg/dL despite standard of supportive care. Patients may
start or adjust anti-diabetic medications to meet eligibility.

12. Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study as so judged by the
treating physician. Examples include but are not limited to:

1. Severely impaired lung function (e.g. use of home O2, history of Idiopathic Lung
Disease (ILD), any evidence of ILD on scan.

2. Active (acute or chronic) or uncontrolled severe infections requiring treatment
with antibiotics

3. Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
hepatitis

4. Uncontrolled hypertension, BP>150/100 despite medical management

5. Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of oral medications (e.g., ulcerative
disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or
small bowel resection)

13. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
recent peripheral arterial thrombosis) within 6 months prior to day 1 of study drug

14. History of hemoptysis (>/= 1/2 teaspoon of bright red blood per episode) within 1
month prior to day 1 of study drug

15. History of abdominal fistula or gastrointestinal perforation at any point within 6
months prior to day 1 of study drug, unless surgically repaired.

16. Use or need for full dose anticoagulation other than low molecular weight heparin
(i.e. Lovenox only with and no other bleeding risk)..

17. Invasion or encasement of a major artery. Abutment without invasion or encasement is
permitted. Abutment is defined as loss of the tissue plane between tumor and vessel
but without invasion of the soft tissues or lumen of the vessel. Encasement is
defined as more than 180 degrees of involvement

18. Serious, non-healing wound, active ulcer, or untreated bone fracture as judged by
treating physician

19. Active, bleeding diathesis

20. Known history of HIV or Hepatitis B or C seropositivity

21. Female patients who are pregnant or breast feeding, or adults of reproductive
potential who are not using effective birth control methods. Two acceptable forms of
contraceptives must be continued throughout the trial by both sexes. Hormonal
contraceptives are not acceptable as a sole method of contraception. (Women of
childbearing potential must have a negative serum pregnancy test within 7 days prior
to day 1 of study drug)

22. Concomitant use of drugs with a risk of causing torsades de pointes (See Appendix 5 )

23. Concomitant use of CYP3A4 inhibitors (See Appendix 6)

24. Patients unwilling to or unable to comply with the protocol

25. Intrathoracic lung carcinoma of squamous cell histology. Mixed tumors will be
categorized by the predominant cell type unless small cell elements are present, in
which case the patient is ineligible; sputum cytology alone is acceptable. Patients
with extrathoracic-only squamous cell NSCLC are eligible. Patients with only
peripheral lung lesions (of any NSCLC histology) will also be eligible (a peripheral
lesion is defined as a lesion in which the epicenter of the tumor is the costal or diaphragmatic pleura in a three-dimensional orientation based on each
lobe of the lung and is